These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

457 related items for PubMed ID: 1102191

  • 1. Patho-anatomical features of the bone marrow.
    Lennert K, Nagai K, Schwarze EW.
    Clin Haematol; 1975 Jun; 4(2):331-51. PubMed ID: 1102191
    [No Abstract] [Full Text] [Related]

  • 2. Bone marrow biopsy (BMB). II. Bone marrow biopsy in myeloproliferative disorders.
    Macavei I, Galatâr N.
    Morphol Embryol (Bucur); 1989 Jun; 35(2):117-27. PubMed ID: 2529429
    [Abstract] [Full Text] [Related]

  • 3. In vitro culture techniques defining biological abnormalities in the myelodysplastic syndromes and myeloproliferative disorders.
    Greenberg PL.
    Clin Haematol; 1986 Nov; 15(4):973-93. PubMed ID: 3552351
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. [Prognostic value of bone marrow biopsy in chronic myeloproliferative disorders].
    Bettini R, Marzetta K, Miglioranza A, Redaelli S, Maino C, Maffiolini A, Gorini M.
    Recenti Prog Med; 2003 Nov; 94(7-8):314-20. PubMed ID: 12868237
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Diagnosis of polycythemia vera based on bone marrow pathology.
    Thiele JM, Kvasnicka HM.
    Curr Hematol Rep; 2005 May; 4(3):218-23. PubMed ID: 15865875
    [Abstract] [Full Text] [Related]

  • 8. The role of beta-catenin in chronic myeloproliferative disorders.
    Jauregui MP, Sanchez SR, Ewton AA, Rice L, Perkins SL, Dunphy CH, Chang CC.
    Hum Pathol; 2008 Oct; 39(10):1454-8. PubMed ID: 18619646
    [Abstract] [Full Text] [Related]

  • 9. [Myeloproliferative disorders].
    Binder D, Fehr J.
    Ther Umsch; 2004 Feb; 61(2):131-42. PubMed ID: 15018396
    [Abstract] [Full Text] [Related]

  • 10. [Clinical course and transformation of polycythemia vera and its relation to applied therapy].
    Burger T, Schmelczer M, Molnár L, Pajor L, Koszorús S.
    Orv Hetil; 1987 Dec 27; 128(52):2723-30. PubMed ID: 3431872
    [No Abstract] [Full Text] [Related]

  • 11. [Acute myelofibrosis--case reports of acute megakaryoblastic leukemia and acute myeloblastic leukemia].
    Ishibashi T, Uchida T, Matsuda S, Sato T, Kimura H, Shichishima T, Mita M, Suzuki A, Kariyone S.
    Rinsho Ketsueki; 1985 Jul 27; 26(7):1145-50. PubMed ID: 3863978
    [No Abstract] [Full Text] [Related]

  • 12. Definition, clinical features and diagnosis of polycythaemia vera.
    Gilbert HS.
    Clin Haematol; 1975 Jun 27; 4(2):263-90. PubMed ID: 1102188
    [No Abstract] [Full Text] [Related]

  • 13. Myelofibrosis--what's in a name? Consensus on definition and EUMNET grading.
    Thiele J, Kvasnicka HM.
    Pathobiology; 2007 Jun 27; 74(2):89-96. PubMed ID: 17587880
    [Abstract] [Full Text] [Related]

  • 14. [Thrombocythaemia - is there a primary form? ((author's transl)].
    Hartwich G, Schirmbeck H, Mörl M.
    Med Klin; 1975 Dec 05; 70(49):2005-8. PubMed ID: 1060913
    [Abstract] [Full Text] [Related]

  • 15. The bone marrow in myeloproliferative and dysmyelopoietic syndromes.
    Wolf BC, Neiman RS.
    Hematol Oncol Clin North Am; 1988 Dec 05; 2(4):669-94. PubMed ID: 3065324
    [Abstract] [Full Text] [Related]

  • 16. Primary polycythaemia. 3. Studies on the significance of the history of the disease and of the treatment for the development of clones in bone marrow cells.
    Visfeldt J, Franzén S, Nielsen A, Tribukait B.
    Acta Pathol Microbiol Scand A; 1973 Mar 05; 81(2):195-203. PubMed ID: 4734062
    [No Abstract] [Full Text] [Related]

  • 17. The diagnosis and management of polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the JAK2 V617F era.
    Zhan H, Spivak JL.
    Clin Adv Hematol Oncol; 2009 May 05; 7(5):334-42. PubMed ID: 19521323
    [Abstract] [Full Text] [Related]

  • 18. Abnormal myelopoietic clones in man.
    McCulloch EA.
    J Natl Cancer Inst; 1979 Oct 05; 63(4):883-92. PubMed ID: 384008
    [No Abstract] [Full Text] [Related]

  • 19. Prognostic factors and models in polycythemia vera, essential thrombocythemia, and primary myelofibrosis.
    Passamonti F.
    Clin Lymphoma Myeloma Leuk; 2011 Jun 05; 11 Suppl 1():S25-7. PubMed ID: 22035744
    [Abstract] [Full Text] [Related]

  • 20. Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.
    Nand S, Stock W, Godwin J, Fisher SG.
    Am J Hematol; 1996 May 05; 52(1):42-6. PubMed ID: 8638610
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.